

Supplementary Figure S2. Individual and mean (\pm standard deviation) area under the curve of tusamitamab ravtansine by dose level after first administration in Cohort Q2W-LD (A) and Cohort Q3W (B).

AUC, area under the plasma concentration versus time curve from time zero extrapolated to infinity; Q2W-LD, cohort receiving a loading dose at Day 1, Cycle 1, followed by a fixed dose every 2 weeks; Q3W, cohort receiving tusamitamab ravtansine every 3 weeks; SD, standard deviation.

